Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pharmaxis Ltd ( (AU:SNT) ) just unveiled an update.
Syntara Limited has announced key strategic appointments to aid in the clinical and commercial development of its lead drug candidate, amsulostat, for myelofibrosis. The new advisors and clinical board members bring extensive experience in haematology and oncology, which is expected to significantly bolster Syntara’s efforts in advancing amsulostat through clinical trials and towards potential market approval. This move is seen as a strategic step to enhance Syntara’s positioning in the drug development industry, particularly in the field of blood cancers.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Syntara Limited is a clinical-stage drug development company specializing in targeting extracellular matrix dysfunction. With expertise in amine oxidase chemistry, Syntara develops novel medicines for blood cancers and conditions related to inflammation and fibrosis. Their lead candidate, amsulostat, is aimed at treating myelofibrosis, a bone marrow cancer. The company is also advancing other drug candidates for various fibrotic and inflammatory diseases and has previously developed respiratory products.
Average Trading Volume: 4,424,039
Technical Sentiment Signal: Sell
Current Market Cap: A$40.81M
For detailed information about SNT stock, go to TipRanks’ Stock Analysis page.